AU Comment: Australian data on rates of virological suppression The 2024 HIV Annual Surveillance Report states there were an estimated 30, 010 people living with HIV in Australia at the end of 2023. Of those, an estimated 92% (27 650) had received an HIV diagnosis. Of those diagnosed, 97% (26,740) were retained in care and …
AU Comment: Weight gain and INSTIs Several reports have identified associations between the use of integrase strand transfer inhibitors (INSTIs) and increased weight and/or body mass index (BMI). It is unclear if this is a causal relationship or is associated with increased morbidity from conditions typically associated with increased weight such as type 2 diabetes …
AU Comment: ART access in Australia The PBS facilitates affordable access to ART, significantly mitigating out-of-pocket costs for patients with Medicare. For example, a concessional PBS co-payment caps prescription costs AUD $7.30 per script (2025). Non-concessional patients pay up to AUD $30.00. Accredited s100 prescribers in the community can assist patients in navigating these subsidies …
This section has information on Drug-Drug Interactions. Please click on the below links or follow the table of contents to access the information you are looking for. Overview NNRTI interactions INSTI interactions HIV-1 gp120-Directed Attachment Inhibitors Interactions between INSTI & NNRTI or PI PI Drug interactions NRTI interactions CCR5 Antagonist Drug Interactions Interactions between PIs …
AU Comment: Additional PK data and resources ARVs requiring specific acidity (e.g. ATV and RPV) may also be affected by the physiological effects of oral supplementation – variable concentration-specific effects of supplementation on gastric pH and absorption of ARVs cannot be excluded as having interaction potential RTV is also an inducer of glucuronosyl transferase (UDP-GT). …
Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. The term “PI” refers to atazanavir (ATV) or darunavir (DRV) boosted with either ritonavir (RTV or r) or cobicistat (COBI or c). This table does not include …
AU Comment: Rilpivirine (RPV) Despite there being no direct effect on RPV plasma concentration, high doses of oral supplements may modify gastric pH, thereby affecting RPV absorption – subsequent potential impact on maintenance of viral suppression. AU Comment: Between-class ARV switching in the context of between-class ARV switches, clinicians may need to factor in enzyme …
Table 24c. Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents) This table provides information on the known or predicted interactions between nucleoside reverse transcriptase inhibitors (NRTIs) and non-antiretroviral drugs. Recommendations for managing a particular drug interaction may differ depending on whether a new antiretroviral (ARV) drug is being initiated in …
This table provides information on the known or predicted interactions between integrase strand transfer inhibitors (INSTIs) (bictegravir [BIC], dolutegravir [DTG], elvitegravir [EVG], or raltegravir [RAL]) and non-antiretroviral (ARV) drugs. EVG is always coadministered with cobicistat. Cabotegravir (CAB) intramuscular (IM) plus rilpivirine (RPV) IM are co-packaged into a single product and are coadministered as a complete …
Table 24e. Drug Interactions Between the CCR5 Antagonist Maraviroc and Other Drugs (Including Antiretroviral Agents) In the table below, “no dose adjustment needed” indicates that the U.S. Food and Drug Administration– approved dose of maraviroc (MVC) 300 mg twice daily should be used. Recommendations for managing a particular drug interaction may differ, depending on whether …
Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM